New Cash Adds To Cardiome’s Bargaining Chips
This article was originally published in The Pink Sheet Daily
Acquisition-hungry big pharma eyes the firm's oral vernakalant, ready for Phase III.
You may also be interested in...
FDA tells biotech the agency will miss once-postponed July 23 user fee date.
Follow-up ATHENA data bolsters NDA called “not approvable” in 2006.
Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.